Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy
jRCT2080223587Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2017
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Jul 2017; status: completed.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2080223587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223587.